© 1996 by Oxford University Press
Journal of the National Cancer Institute, Vol. 88, No. 17, 1210-1215,
September 4, 1996
© 1996 Oxford University Press
Improved Survival in Stage III Non-Small-Cell Lung Cancer: Seven-Year Follow-up of Cancer and Leukemia Group B (CALGB) 8433 Trial
Hoag Cancer Center Newport Beach, CA
University of California San Diego
Duke University Medical Center Durham, NC
Dartmouth Medical School Hanover, NH
Robert O. Dillman, M.D., Hoag Cancer Center, 301 Newport Blvd., Newport Beach, CA 92663.
BACKGROUND:: For many years, high-dose radiation therapy was the standard treatment for patients with locally or regionally advanced non-small-cell lung cancer (NSCLC), despite a 5-year survival rate of only 3%–10% following such therapy. From May 1984 through May 1987, the Cancer and Leukemia Group B (CALGB) conducted a randomized trial that showed that induction chemotherapy before radiation therapy improved survival during the first 3 years of follow-up.
PURPOSE:: This report provides data for 7 years of follow-up of patients enrolled in the CALGB trial.
METHODS:: The patient population consisted of individuals who had clinical or surgical stage III, histologically documented NSCLC; a CALGB performance status of 0–1; less than 5% loss of body weight in the 3 months preceding diagnosis; and radiographically visible disease. Patients were randomly assigned to receive either 1) cisplatin (100 mg/m2 body surface area intravenously on days 1 and 29) and vinblastine (5 mg/m2 body surface area intravenously weekly on days 1, 8, 15, 22, and 29) followed by radiation therapy with 6000 cGy given in 30 fractions beginning on day 50 (CT-RT group) or 2) radiation therapy with 6000 cGy alone beginning on day 1(RT group) for a maximum duration of 6–7 weeks. Patients were evaluated for tumor regression if they had measurable or evaluable disease and were monitored for toxic effects, disease progression, and date of death.
RESULTS:: There were 78 eligible patients randomly assigned to the CT-RT group and 77 randomly assigned to the RT group. Both groups were similar in terms of sex, age, histologic cell type, performance status, substage of disease, and whether staging had been clinical or surgical. All patients had measurable or evaluable disease at the time of random assignment to treatment groups. Both groups received a similar quantity and quality of radiation therapy. As previously reported, the rate of tumor response, as determined radiographically, was 56% for the CT-RT group and 43% for the RT group (P = .092). After more than 7 years of follow-up, the median survival remains greater for the CT-RT group (13.7 months) than for the RT group (9.6 months) (P = .012) as ascertained by the logrank test (two-sided). The percentages of patients surviving after years 1 through 7 were 54, 26, 24, 19, 17, 13, and 13 for the CT-RT group and 40, 13, 10, 7, 6, 6, and 6 for the RT group.
CONCLUSIONS:: Long-term follow-up confirms that patients with stage III NSCLC who receive 5 weeks of chemotherapy with cisplatin and vinblastine before radiation therapy have a 4.1-month increase in median survival. The use of sequential chemotherapy-radiotherapy increases the projected proportion of 5-year survivors by a factor of 2.8 compared with that of radiotherapy alone. However, inasmuch as 80%–85% of such patients still die within 5 years and because treatment failure occurs both in the irradiated field and at distant sites in patients receiving either sequential chemotherapy-radiotherapy or radio-therapy alone, the need for further improvements in both the local and systemic treatment of this disease persists. [J Natl Cancer Inst 1996;88:1210–5]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. Fujii, H. Kunikane, H. Okamoto, K. Watanabe, H. Kunitoh, K. Mori, A. Yokoyama, H. Fukuda, T. Tamura, and N. Saijo A Phase II Study of Cisplatin and Irinotecan as Induction Chemotherapy Followed by Accelerated Hyperfractionated Thoracic Radiotherapy with Daily Low-dose Carboplatin in Unresectable Stage III Non-small Cell Lung Cancer: JCOG 9510 Jpn. J. Clin. Oncol., September 20, 2009; (2009) hyp102v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-x. Yang, X. Hou, P. Lin, T.-h. Rong, H. Yang, and J.-h. Fu Survival and risk factors of surgically treated mediastinal invasion T4 non-small cell lung cancer. Ann. Thorac. Surg., August 1, 2009; 88(2): 372 - 378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Steger, T. Walles, B. Kosan, T. Walker, T. Kyriss, S. Veit, J. Dippon, and G. Friedel Trimodal Therapy for Histologically Proven N2/3 Non-Small Cell Lung Cancer: Mid-Term Results and Indicators for Survival. Ann. Thorac. Surg., June 1, 2009; 87(6): 1676 - 1683. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Kandioler, G. Stamatis, W. Eberhardt, S. Kappel, S. Zochbauer-Muller, I. Kuhrer, M. Mittlbock, R. Zwrtek, C. Aigner, C. Bichler, et al. Growing clinical evidence for the interaction of the p53 genotype and response to induction chemotherapy in advanced non-small cell lung cancer. J. Thorac. Cardiovasc. Surg., May 1, 2008; 135(5): 1036 - 1041. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Rosenzweig In Reply J. Clin. Oncol., May 1, 2008; 26(13): 2235 - 2236. [Full Text] [PDF]
|
|
|
|
|
|
R. Glynne-Jones and P. Hoskin Neoadjuvant Cisplatin Chemotherapy Before Chemoradiation: A Flawed Paradigm? J. Clin. Oncol., November 20, 2007; 25(33): 5281 - 5286. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. W. Blackstock and R. Govindan Definitive Chemoradiation for the Treatment of Locally Advanced Non Small-Cell Lung Cancer J. Clin. Oncol., September 10, 2007; 25(26): 4146 - 4152. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Robinson, J. C. Ruckdeschel, H. Wagner Jr, and C. W. Stevens Treatment of Non-small Cell Lung Cancer-Stage IIIA: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 243S - 265S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. E. Vokes, J. E. Herndon II, M. J. Kelley, M. G. Cicchetti, N. Ramnath, H. Neill, J. N. Atkins, D. M. Watson, W. Akerley, and M. R. Green Induction Chemotherapy Followed by Chemoradiotherapy Compared With Chemoradiotherapy Alone for Regionally Advanced Unresectable Stage III Non-Small-Cell Lung Cancer: Cancer and Leukemia Group B J. Clin. Oncol., May 1, 2007; 25(13): 1698 - 1704. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P H Jarritt, K J Carson, A R Hounsell, and D Visvikis The role of PET/CT scanning in radiotherapy planning Br. J. Radiol., September 1, 2006; 79(Special_Issue_1): S27 - S35. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. E. Stinchcombe, D. Fried, D. E. Morris, and M. A. Socinski Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer Oncologist, July 1, 2006; 11(7): 809 - 823. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. E. Vokes, M. C. Perry, H. L. Kindler, and M. R. Green The cancer and leukemia group B respiratory committee. Clin. Cancer Res., June 1, 2006; 12(11): 3581s - 3588s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Sugimura and P. Yang Long-term Survivorship in Lung Cancer: A Review. Chest, April 1, 2006; 129(4): 1088 - 1097. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. N. Myers, K. M. O'Neil, T. E. Walsh, K. J. Hoffmeister, D. J. Venzon, and B. E. Johnson The Pulmonary Status of Patients With Limited-Stage Small Cell Lung Cancer 15 Years After Treatment With Chemotherapy and Chest Irradiation Chest, November 1, 2005; 128(5): 3261 - 3268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P H Jarritt, A R Hounsell, K J Carson, D Visvikis, V P Cosgrove, J C Clarke, D P Stewart, V A L Fleming, R L Eakin, and A Zatari Use of combined PET/CT images for radiotherapy planning: initial experiences in lung cancer Br. J. Radiol., November 1, 2005; Supplement_28(1): 33 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. G. Divers, S. A. Spencer, D. Carey, E. M. Busby, M. D. Hyatt, and F. Robert Phase I/IIa Study of Cisplatin and Gemcitabine As Induction Chemotherapy Followed by Concurrent Chemoradiotherapy With Gemcitabine and Paclitaxel for Locally Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., September 20, 2005; 23(27): 6664 - 6673. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Wee, E. H. Tan, B. C. Tai, H. B. Wong, S. S. Leong, T. Tan, E. T. Chua, E. Yang, K. M. Lee, K. W. Fong, et al. Randomized Trial of Radiotherapy Versus Concurrent Chemoradiotherapy Followed by Adjuvant Chemotherapy in Patients With American Joint Committee on Cancer/International Union Against Cancer Stage III and IV Nasopharyngeal Cancer of the Endemic Variety J. Clin. Oncol., September 20, 2005; 23(27): 6730 - 6738. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Choy, A. Nabid, B. Stea, C. Scott, W. Roa, L. Kleinberg, J. Ayoub, C. Smith, L. Souhami, S. Hamburg, et al. Phase II Multicenter Study of Induction Chemotherapy Followed by Concurrent Efaproxiral (RSR13) and Thoracic Radiotherapy for Patients With Locally Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., September 1, 2005; 23(25): 5918 - 5928. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. E. Vokes Optimal Therapy for Unresectable Stage III Non-Small-Cell Lung Cancer J. Clin. Oncol., September 1, 2005; 23(25): 5853 - 5855. [Full Text] [PDF]
|
|
|
|
|
|
C. P. Belani, H. Choy, P. Bonomi, C. Scott, P. Travis, J. Haluschak, and W. J. Curran Jr Combined Chemoradiotherapy Regimens of Paclitaxel and Carboplatin for Locally Advanced Non-Small-Cell Lung Cancer: A Randomized Phase II Locally Advanced Multi-Modality Protocol J. Clin. Oncol., September 1, 2005; 23(25): 5883 - 5891. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. E. Vokes, J. Crawford, J. Bogart, M. A. Socinski, G. Clamon, and M. R. Green Concurrent Chemoradiotherapy for Unresectable Stage III Non-Small Cell Lung Cancer Clin. Cancer Res., July 1, 2005; 11(13): 5045s - 5050s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Gandara, S. Narayan, P. N. Lara Jr., Z. Goldberg, A. Davies, D. H.M. Lau, P. Mack, P. Gumerlock, and S. Vijayakumar Integration of Novel Therapeutics into Combined Modality Therapy of Locally Advanced Non-Small Cell Lung Cancer Clin. Cancer Res., July 1, 2005; 11(13): 5057s - 5062s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. P. Belani, W. Wang, D. H. Johnson, H. Wagner, J. Schiller, M. Veeder, and M. Mehta Phase III Study of the Eastern Cooperative Oncology Group (ECOG 2597): Induction Chemotherapy Followed by Either Standard Thoracic Radiotherapy or Hyperfractionated Accelerated Radiotherapy for Patients With Unresectable Stage IIIA and B Non-Small-Cell Lung Cancer J. Clin. Oncol., June 1, 2005; 23(16): 3760 - 3767. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Farray, N. Mirkovic, and K. S. Albain Multimodality Therapy for Stage III Non-Small-Cell Lung Cancer J. Clin. Oncol., May 10, 2005; 23(14): 3257 - 3269. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Liao, R. Komaki, L. Milas, C. Yuan, M. Kies, J. Y. Chang, M. Jeter, T. Guerrero, G. Blumenschien, C. M. Smith, et al. A Phase I Clinical Trial of Thoracic Radiotherapy and Concurrent Celecoxib for Patients with Unfavorable Performance Status Inoperable/Unresectable Non-Small Cell Lung Cancer Clin. Cancer Res., May 1, 2005; 11(9): 3342 - 3348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Mamon, B. Y. Yeap, P. A. Janne, J. Reblando, S. Shrager, M. T. Jaklitsch, S. Mentzer, J. M. Lukanich, D. J. Sugarbaker, E. H. Baldini, et al. High Risk of Brain Metastases in Surgically Staged IIIA Non-Small-Cell Lung Cancer Patients Treated With Surgery, Chemotherapy, and Radiation J. Clin. Oncol., March 1, 2005; 23(7): 1530 - 1537. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Jeremic, B. Milicic, L. Acimovic, and S. Milisavljevic Concurrent Hyperfractionated Radiotherapy and Low-Dose Daily Carboplatin and Paclitaxel in Patients With Stage III Non-Small-Cell Lung Cancer: Long-Term Results of a Phase II Study J. Clin. Oncol., February 20, 2005; 23(6): 1144 - 1151. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. B. Marks, J. Garst, M. A. Socinski, G. Sibley, A. W. Blackstock, J. E. H. S. Zhou, T. Shafman, A. Tisch, R. Clough, X. Yu, et al. Carboplatin/Paclitaxel or Carboplatin/Vinorelbine Followed by Accelerated Hyperfractionated Conformal Radiation Therapy: Report of a Prospective Phase I Dose Escalation Trial From the Carolina Conformal Therapy Consortium J. Clin. Oncol., November 1, 2004; 22(21): 4329 - 4340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Socinski, D. E. Morris, J. S. Halle, D. T. Moore, T. A. Hensing, S. A. Limentani, R. Fraser, M. Tynan, A. Mears, M. P. Rivera, et al. Induction and Concurrent Chemotherapy With High-Dose Thoracic Conformal Radiation Therapy in Unresectable Stage IIIA and IIIB Non-Small-Cell Lung Cancer: A Dose-Escalation Phase I Trial J. Clin. Oncol., November 1, 2004; 22(21): 4341 - 4350. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. C. Archie and C. R. Thomas Jr. Superior Sulcus Tumors: A Mini-Review Oncologist, September 1, 2004; 9(5): 550 - 555. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Socinski, C. Zhang, J. E. Herndon II, R. O. Dillman, G. Clamon, E. Vokes, W. Akerley, J. Crawford, M. C. Perry, S. L. Seagren, et al. Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity Ann. Onc., July 1, 2004; 15(7): 1033 - 1041. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Friedberg, R. Mick, J. P. Stevenson, T. Zhu, T. M. Busch, D. Shin, D. Smith, M. Culligan, A. Dimofte, E. Glatstein, et al. Phase II Trial of Pleural Photodynamic Therapy and Surgery for Patients With Non-Small-Cell Lung Cancer With Pleural Spread J. Clin. Oncol., June 1, 2004; 22(11): 2192 - 2201. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Eberhardt, M. Stuschke, and G. Stamatis Preoperative chemoradiation approaches to locally advanced non-small-cell lung cancer: one man's pride, another man's burden? Ann. Onc., March 1, 2004; 15(3): 365 - 367. [Full Text] [PDF]
|
|
|
|
|
|
J.-P. Sculier, J.-J. Lafitte, T. Berghmans, P. Van Houtte, J. Lecomte, J. Thiriaux, A. Efremidis, G. Koumakis, V. Giner, M. Richez, et al. A phase III randomised study comparing two different dose-intensity regimens as induction chemotherapy followed by thoracic irradiation in patients with advanced locoregional non-small-cell lung cancer Ann. Onc., March 1, 2004; 15(3): 399 - 409. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Spira and D. S. Ettinger Multidisciplinary Management of Lung Cancer N. Engl. J. Med., January 22, 2004; 350(4): 379 - 392. [Full Text] [PDF]
|
|
|
|
|
|
D. G. Pfister, D. H. Johnson, C. G. Azzoli, W. Sause, T. J. Smith, S. Baker Jr, J. Olak, D. Stover, J. R. Strawn, A. T. Turrisi, et al. American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline: Update 2003 J. Clin. Oncol., January 15, 2004; 22(2): 330 - 353. [Full Text] [PDF]
|
|
|
|
|
|
L. V. Sequist and T. J. Lynch Aggressive Treatment for the Fit Elderly With Non-Small-Cell Lung Cancer? Yes! J. Clin. Oncol., September 1, 2003; 21(17): 3186 - 3188. [Full Text] [PDF]
|
|
|
|
|
|
S. E. Schild, P. J. Stella, S. M. Geyer, J. A. Bonner, W. L. McGinnis, J. A. Mailliard, J. Brindle, A. Jatoi, and J. R. Jett The Outcome of Combined-Modality Therapy for Stage III Non-Small-Cell Lung Cancer in the Elderly J. Clin. Oncol., September 1, 2003; 21(17): 3201 - 3206. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. V. Scagliotti and A. T. Turrisi III Docetaxel-Based Combined-Modality Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer Oncologist, August 1, 2003; 8(4): 361 - 374. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Gandara, K. Chansky, K. S. Albain, B. R. Leigh, L. E. Gaspar, P. N. Lara Jr, H. Burris, P. Gumerlock, J. P. Kuebler, J. D. Bearden III, et al. Consolidation Docetaxel After Concurrent Chemoradiotherapy in Stage IIIB Non-Small-Cell Lung Cancer: Phase II Southwest Oncology Group Study S9504 J. Clin. Oncol., May 15, 2003; 21(10): 2004 - 2010. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Leong, E. H. Tan, K. W. Fong, E. Wilder-Smith, Y. K. Ong, B. C. Tai, L. Chew, S. H. Lim, J. Wee, K. M. Lee, et al. Randomized Double-Blind Trial of Combined Modality Treatment With or Without Amifostine in Unresectable Stage III Non-Small-Cell Lung Cancer J. Clin. Oncol., May 1, 2003; 21(9): 1767 - 1774. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. Wirth, J. Lucca, P. Ostler, P. Fidias, C. Lynch, P. A. Janne, R. S. Herbst, B. E. Johnson, D. J. Sugarbaker, D. J. Mathisen, et al. Induction Docetaxel and Carboplatin Followed by Weekly Docetaxel and Carboplatin with Concurrent Radiotherapy, then Surgery in Stage III Non-Small Cell Lung Cancer: A Phase I Study Clin. Cancer Res., May 1, 2003; 9(5): 1698 - 1704. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Jett, W. J. Scott, M. P. Rivera, and W. T. Sause Guidelines on Treatment of Stage IIIB Non-small Cell Lung Cancer Chest, January 1, 2003; 123 (2009): 221S - 225S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. Spiro and J. C. Porter Lung Cancer--Where Are We Today?: Current Advances in Staging and Nonsurgical Treatment Am. J. Respir. Crit. Care Med., November 1, 2002; 166(9): 1166 - 1196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. E. Vokes, J. E. Herndon II, J. Crawford, K. A. Leopold, M. C. Perry, A. A. Miller, and M. R. Green Randomized Phase II Study of Cisplatin With Gemcitabine or Paclitaxel or Vinorelbine as Induction Chemotherapy Followed by Concomitant Chemoradiotherapy for Stage IIIB Non-Small-Cell Lung Cancer: Cancer and Leukemia Group B Study 9431 J. Clin. Oncol., October 15, 2002; 20(20): 4191 - 4198. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. S. Albain, J. J. Crowley, A. T. Turrisi III, D. R. Gandara, W. B. Farrar, J. I. Clark, K. R. Beasley, and R. B. Livingston Concurrent Cisplatin, Etoposide, and Chest Radiotherapy in Pathologic Stage IIIB Non-Small-Cell Lung Cancer: A Southwest Oncology Group Phase II Study, SWOG 9019 J. Clin. Oncol., August 15, 2002; 20(16): 3454 - 3460. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Hahn, E. J. Bernhard, W. Regine, M. Mohiuddin, D. G. Haller, J. P. Stevenson, D. Smith, B. Pramanik, J. Tepper, T. F. DeLaney, et al. A Phase I Trial of the Farnesyltransferase Inhibitor L-778,123 and Radiotherapy for Locally Advanced Lung and Head and Neck Cancer Clin. Cancer Res., May 1, 2002; 8(5): 1065 - 1072. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Pottgen, W. Eberhardt, S. Bildat, G. Stuben, G. Stamatis, L. Hillejan, S. Sohrab, H. Teschler, S. Seeber, H. Sack, et al. Induction chemotherapy followed by concurrent chemotherapy and definitive high-dose radiotherapy for patients with locally advanced non-small-cell lung cancer (stages IIIa/IIIb): a pilot phase I/II trial Ann. Onc., March 1, 2002; 13(3): 403 - 411. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Sekine, Y. Nishiwaki, T. Ogino, A. Yokoyama, M. Saito, K. Mori, I. Tsukiyama, S. Tsuchiya, K. Hayakawa, K. Yoshimura, et al. Phase II Study of Twice-Daily High-Dose Thoracic Radiotherapy Alternating With Cisplatin and Vindesine for Unresectable Stage III Non-Small-Cell Lung Cancer: Japan Clinical Oncology Group Study 9306 J. Clin. Oncol., February 1, 2002; 20(3): 797 - 803. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. B. Wallace, G. A. Silvestri, A. V. Sahai, R. H. Hawes, B. J. Hoffman, V. Durkalski, W. S. Hennesey, and C. E. Reed Endoscopic ultrasound-guided fine needle aspiration for staging patients with carcinoma of the lung Ann. Thorac. Surg., December 1, 2001; 72(6): 1861 - 1867. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Tsuchiya, Y. Ohe, T. Sugiura, N. Fuwa, Y. Kitamoto, K. Mori, H. Kobayashi, K. Nakata, T. Sawa, K. Hirai, et al. Randomized Phase I Study of Standard-fractionated or Accelerated-hyperfractionated Radiotherapy with Concurrent Cisplatin and Vindesine for Unresectable Non-Small Cell Lung Cancer: a Report of Japan Clinical Oncology Group Study (JCOG 9601) Jpn. J. Clin. Oncol., October 1, 2001; 31(10): 488 - 494. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Grunenwald, F. Andre, C. Le Pechoux, P. Girard, C. Lamer, A. Laplanche, M. Tarayre, R. Arriagada, and T. Le Chevalier Benefit of surgery after chemoradiotherapy in stage IIIB (T4 and/or N3) non-small cell lung cancer J. Thorac. Cardiovasc. Surg., October 1, 2001; 122(4): 796 - 802. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Brundage, D. Feldman-Stewart, R. Cosby, R. Gregg, P. Dixon, Y. Youssef, D. Davies, and W. J. Mackillop Phase I Study of a Decision Aid for Patients With Locally Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., March 1, 2001; 19(5): 1326 - 1335. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. D. Maguire, L. B. Marks, G. S. Sibley, J. E. Herndon II, R. W. Clough, K. L. Light, M. L. Hernando, P. A. Antoine, and M. S. Anscher 73.6 Gy and Beyond: Hyperfractionated, Accelerated Radiotherapy for Non-Small-Cell Lung Cancer J. Clin. Oncol., February 1, 2001; 19(3): 705 - 711. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Andre, D. Grunewald, and T. Le Chevalier Persistence of viable tumor cells after radiation and chemotherapy for stage IIIB non-small cell lung cancer: An early marker of treatment failure J. Thorac. Cardiovasc. Surg., February 1, 2001; 121(2): 403 - 403. [Full Text] [PDF]
|
|
|
|
|
|
J. A. Hayman, M. K. Martel, R. K. Ten Haken, D. P. Normolle, R. F. Todd III, J. F. Littles, M. A. Sullivan, P. W. Possert, A. T. Turrisi, and A. S. Lichter Dose Escalation in Non-Small-Cell Lung Cancer Using Three-Dimensional Conformal Radiation Therapy: Update of a Phase I Trial J. Clin. Oncol., January 1, 2001; 19(1): 127 - 136. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Andre, D. Grunenwald, J.-P. Pignon, A. Dujon, J. L. Pujol, P. Y. Brichon, L. Brouchet, E. Quoix, V. Westeel, and T. Le Chevalier Survival of Patients With Resected N2 Non-Small-Cell Lung Cancer: Evidence for a Subclassification and Implications J. Clin. Oncol., August 16, 2000; 18(16): 2981 - 2989. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Johnson Locally Advanced, Unresectable Non-Small Cell Lung Cancer : New Treatment Strategies Chest, April 1, 2000; 117 (2009): 123S - 126S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Sause, P. Kolesar, S. Taylor IV, D. Johnson, R. Livingston, R. Komaki, B. Emami, W. Curran Jr., R. Byhardt, A. R. Dar, et al. Final Results of Phase III Trial in Regionally Advanced Unresectable Non-Small Cell Lung Cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group Chest, February 1, 2000; 117(2): 358 - 364. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. T. Sause The Role of Radiotherapy in Non-Small Cell Lung Cancer* Chest, December 1, 1999; 116 (2009): 504S - 508S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Strauss Role of Chemotherapy in Stages I to III Non-small Cell Lung Cancer* Chest, December 1, 1999; 116 (2009): 509S - 516S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Cullen, L. J. Billingham, C. M. Woodroffe, A. D. Chetiyawardana, N. H. Gower, R. Joshi, D. R. Ferry, R. M. Rudd, S. G. Spiro, J. E. Cook, et al. Mitomycin, Ifosfamide, and Cisplatin in Unresectable Non–Small-Cell Lung Cancer: Effects on Survival and Quality of Life J. Clin. Oncol., October 1, 1999; 17(10): 3188 - 3194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Lynch Jr. Lung Cancer Highlights Oncologist, August 1, 1999; 4(4): 279 - 286. [Full Text]
|
|
|
|
|
|
P. Comella, G. Frasci, N. Panza, L. Manzione, V. Lorusso, G. Di Rienzo, R. Cioffi, G. De Cataldis, L. Maiorino, D. Bilancia, et al. Cisplatin, Gemcitabine, and Vinorelbine Combination Therapy in Advanced Non–Small-Cell Lung Cancer: A Phase II Randomized Study of the Southern Italy Cooperative Oncology Group J. Clin. Oncol., May 1, 1999; 17(5): 1526 - 1526. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Kandioler-Eckersberger, S. Kappel, M. Mittlbock, G. Dekan, C. Ludwig, E. Janschek, R. Pirker, E. Wolner, and F. Eckersberger THE TP53 GENOTYPE BUT NOT IMMUNOHISTOCHEMICAL RESULT IS PREDICTIVE OF RESPONSE TO CISPLATIN-BASED NEOADJUVANT THERAPY IN STAGE III NON-SMALL CELL LUNG CANCER J. Thorac. Cardiovasc. Surg., April 1, 1999; 117(4): 744 - 750. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Clamon, J. Herndon, R. Cooper, A. Y. Chang, J. Rosenman, and M. R. Green Radiosensitization With Carboplatin for Patients With Unresectable Stage III Non–Small-Cell Lung Cancer: A Phase III Trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group J. Clin. Oncol., January 1, 1999; 17(1): 4 - 4. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Leong, C. M. Rocha Lima, C. A. Sherman, and M. R. Green The 1997 International Staging System for Non-Small Cell Lung Cancer: Have All the Issues Been Addressed? Chest, January 1, 1999; 115(1): 242 - 248. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. W. Rice, D. J. Adelstein, J. P. Ciezki, M. E. Becker, L. A. Rybicki, C. F. Farver, M. A. Larto, and E. H. Blackstone Short-course induction chemoradiotherapy with paclitaxel for stage III non-small-cell lung cancer Ann. Thorac. Surg., December 1, 1998; 66(6): 1909 - 1914. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Pretreatment Evaluation of Non-Small-cell Lung Cancer Am. J. Respir. Crit. Care Med., July 1, 1997; 156(1): 320 - 332. [Full Text]
|
|